

# Investors Relations Presentation

Qatari German Medical Devices First Quarter , 2020 www.qgmd.com



The following presentation is made only to, and is directed only at, persons to whom such a presentation may lawfully be communicated ("relevant persons"). Any person who is not a relevant person should not act or rely on this presentation or any of its contents.

This presentation contains forward-looking statements that are subject to risks and uncertainties, including statements about QGMD 's beliefs and expectations.

These forward-looking statements are based on assumptions that QGMD has made in light of its experience in the industry in which it operates, as well as its perceptions of historical trends, current conditions, expected future developments and other factors which QGMD believes are appropriate under the circumstances. Prospective investors should understand that these statements are not guarantees of future performance or results.

Due to these factors, QGMD cautions that prospective investors should not place undue reliance on any

forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made.

New risks and uncertainties arise from time-to-time, and it is impossible to predict these events or how they may affect QGMD.





### Agenda

Company Overview
QGMD Production facilities & Machineries
Recognition & Quality Assurance at QGMD

≻What we do?

>QGMD News

➤Sales Figures

Financial HighlightsStatement of Comprehensive Income

### Company Overview

- QG Medical Devices is one of the leading manufacturers of Medical Devices in the Middle East and the only Manufacturing Company producing syringes and IV cannulas in Qatar. Headquartered in Doha, Qatar.
- QG Medical Devices Co. was established in the year 2000, with collaboration of a German Company to produce high quality medical devices in Qatar; utilizing best of breed technology and machines.
- QG Medical Devices is a Public Listed Company in Qatar Stock Exchange. Top Governmental Organizations are the major Share Holders.





### QGMD Production Facilities & Machineries

QG Medical Devices is equipped with state of art production facility designed by reputable innovative technology providers from Germany, Switzerland and Italy.



### **Recognitions & Quality Accreditation**






### **Quality in Focus**











### **Certification and Accreditation**





# QG Fight Against COVID19





# QG Control Measures Against COVID19

Employers have an important role to play in protecting workers from COVID-19 and keeping them healthy and safe. Actions that employers should take include:



Raising awareness of the recommended measures to prevent the spread of COVID-19 by providing easily available educational materials in the languages spoken by employees.



Cleaning and sterilising work sites, housing, bathrooms, kitchens, buses, and others frequently used locations daily.



Distributing masks, soap, hand sanitizers, tissues, and advising employees on proper handwashing.



Training employees on how to apply preventative measures at work and home to decrease their susceptibility to the virus.




Ensuring that workers are regularly screened and tested for the virus.



## QG Control Measures Against COVID19









**CHECK IS REQUIRED** 





# World Health Organization Accreditation for Q SAFE Re-Use Prevention Syringes



E013:	Hypodermic syringes with reuse prevention feature
PQS code:	E013/087
Description:	RUP syringe 2ml
Manufacturer's reference:	Q-Safe® 2-3ml
Manufactured in:	Qatar
Company:	Qatari German Company for Medical Devices
Address:	P.O.Box 22556 ABU HAMOUR DOHA, STATE OF QATAR
Telephone:	+974 44581201
Email:	sales@qgmd.com
Web address:	www.qgmd.com

#### **Specifications**

Graduations:	0.1ml	Needle size:	23G x 1"
Syringe material(s):	Polypropylene	Other needle options:	Yes
Number of components:	3 pieces	Needle fixation:	Fixed
RUP mechanism:	Retraction of needle and plunger break	Primary packaging:	Paper blister pack
RUP location:	Upon completion of injection	CE mark:	Yes
RUP type:	Type I B		
Pieces per carton:	1000	Volume per carton (m3):	0.08m3
Minimum order:	100000	Weight per carton (kg):	4.2kg
Year base price:	2013	Incoterms:	EXW
Price per unit:	0.067USD		
Quality standard:	- ISO 9001 - ISO 13485 -		
Comments:	100 units per pack		
Current PQS status:	pre-qualified; 25 Apr 2013	Valid until	May, 2020

Performanc	e Quality S.	AFETY
1	E013:	Hypodermic syringes with reuse prevention feature
	PQS code:	E013/088
	Description:	RUP syringe 5ml
	Manufacturer's reference:	Q-Safe® 5-6ml
2	Manufactured in:	Qatar
	Company:	Qatari German Company for Medical Devices
	Address:	P.O.Box 22556 ABU HAMOUR DOHA, STATE OF QATAR
	Telephone:	+974 4458 1201
	Email:	sales@qgmd.com
	Web address:	www.qgmd.com

#### Specifications

Graduations:	0.5ml	Needle size:	23G x 1"
Syringe material(s):	Polypropylene	Other needle options:	Yes
Number of components:	3 pieces	Needle fixation:	Fixed
RUP mechanism:	Needle retraction and plunger break	Primary packaging:	Paper blister pack
RUP location:	Upon completion of injection	CE mark:	Yes
RUP type:	Type I B		
Pieces per carton:	1000	Volume per carton (m3):	0.09m3
Minimum order:	100000	Weight per carton (kg):	6.5kg
Year base price:	2013	Incoterms:	EXW
Price per unit:	0.080USD		
Quality standard:	- ISO 9001 - ISO 13485 -		
Comments:			
Current PQS status:	pre-qualified; 25 Apr 2013	Valid until	May, 2020
with the states of the states	the state state of the state of		

Note: If Current PQS status is 'Suspended' or 'Withdrawn',

Note: If Current PQS status is 'Suspended' or 'Withdrawn



# What We Do?

QGMD is striving to become a leading medical devices manufacturer in the healthcare industry worldwide, as well as a strong partner in the medical trading and services industry; by continuing to introduce innovative and superior medical devices which guarantee better patient care.

- We strive :
- To introduce cutting edge solutions to the medical devices industry whereby Patient and Medical Staff Care are the core of our innovation
- To provide the international health community with safe, effective, and efficient medical devices of the highest quality.
- To reduce/eliminate (where possible) any potential risks associated with Medical industry .
- To guarantee a continued R&D and investment to produce innovative medical devices for the benefit of our patients and medical staff, and the community as a whole.
- To increase the trading and services lines by acquiring more medical partnership with local, regional and international agencies.
- QGMD is committed to develop innovative products that meet the requirements of the local and international market.





















### QGMD News

- In coordination with Qatar Chamber & QDB, Qatari German For Medical Devices Company participated in Made in Qatar Expo which was held in Kuwait from 19 – 22 Feb 2020.
- Managing an increase of the sales by opening local, regional & global market with taking into the account the risk assessment and challenges of these markets and the ease of trade in some countries in the world. We are currently exporting to Iraq, Malaysia, Kuwait, Pakistan, Romania, Germany, Poland, Cyprus after covering all the needs of the local market. We are in line with Qatar National Vision 2030 and in response to the quest of many investors to participate in our facility production and opening new markets.
- Alignment with the strategic objective's by diversifying the business and sources of income. We have obtained Alicen's to open medical warehouse to obtain international drug distribution agencies covering the need of the local market.

### From Qatar to the World QGMD - Global Leader in Medical Device Technology





Oman	Philippines
UNICEF	Sudan
Papua New Guinea	Pakistan
Iran	Cyprus
Iraq	Switzerland
Libya	Poland South America
Romania	(P.A.H.O.)
Malaysia	Uganda

"The safety of individuals and society in the State of Qatar, is our top priority"



## QGMD News

In coordination with Ministry of Commerce & Industry & to support Govt decision to mandatory wear face mask QGMD worked in terms of Social responsibility to ensure a Strategic stock of 3 Ply Surgical Face Masks up to 10 Million Pcs & more to come.





## QGMD News

#### • COVID - 19

• QGMD is committed to supply all Medical products which may help Paramedic Staff , Patients & other people. To do that we have the below items in Pipeline to serve the community.

Face Shield , Goggles , N95 Masks & PPE












	31. March,2020 (QR.)	31, December 2019 (QR.)
ASSETS	(Unaudited)	(Audited)
NON-CURRENT ASSETS		
Property, plant, equipment and capital work in progress	114,902,149	116,286,878
Investment properties	12,590,000	12,590,000
Right-of-use assets	106,871	106,871
Intangible assets	10,329,937	10,329,937
Total Non-Current Assets	137,928,957	139,313,686
CURRENT ASSETS		
Inventories	11,070,741	11,271,253
Accounts and other receivables	5,783,061	2,581,390
Cash in hand and at banks	1,670,950	961,908
Total Current Assets	18,524,753	14,814,551
Total Assets	156,453,710	154,128,237
EQUITY AND LIABILITIES		
<u>EQUITY</u>		
Share capital	115,500,000	115,500,000
Legal reserve	30,343,120	30,343,120
Revaluation reserve	11,999,694	11,999,694
Accumulated losses	(129,574,462)	(127,195,066)
Net Equity	28,268,352	30,647,748
NON-CURRENT LIABILITIES		<u> </u>
Employees' end of service benefits	953,672	997,117
Loans and borrowings - long term portion	97,134,857	99,968,055
Lease liabilities -long term portion	97,529	97,529
Total Non-Current Liabilities	98,186,059	101,062,701
CURRENT LIABILITIES		
Loans and borrowings - short term portion	7,311,036	4,800,102
Lease liabilities -short term portion	29,268	8,032
Accounts and other payables	7,529,097	
Bank overdraft	15,129,899	15,154,640
Total Current Liabilities	29,999,299	22,417,788
Total Liabilities	128,185,358	123,480,489
Total Equity and Liabilities	156,453,710	154,128,237




#### STATEMENT OF FINANCIAL POSITION AS ON MARCH 31, 2020



(Unaudited)     (Unaudited)       Revenue     2,055,032     2,756,769       Operating cost (Except Depreciation)     (1,590,606)     (2,580,834)		31. March 2020 (QR.)	31. March 2019 (QR.)
Operating cost (Except Depreciation)   (1,590,606)   (2,580,834)     Gross profit   464,425   175,936     Other income   618,187   610,213     Selling and distribution expenses   (34,625)   (89,096)     General and administrative expenses   (1,191,447)   (1,246,897)     Depreciation and amortization   (1,381,579)   (1,299,759)     Operating (loss) before finance cost for the year   (1,525,039)   (1,849,603)     Finance cost   (855,820)   (1,150,395)     Income (Loss) for the period   (2,380,859)   (2,999,998)     Total comprehensive income   -0-   -0-     Income (Loss) per share   (2,380,859)   (2,999,998)     Image: Select and diluted (loss) per share (QR.)   (0.021)   (0.026)		(Unaudited)	(Unaudited)
Gross profit   464,425   175,936     Other income   618,187   610,213     Selling and distribution expenses   (34,625)   (89,096)     General and administrative expenses   (1,191,447)   (1,246,897)     Depreciation and amortization   (1,381,579)   (1,299,759)     Operating (loss) before finance cost for the year   (1,525,039)   (1,849,603)     Finance cost   (855,820)   (1,150,395)     Income (Loss) for the period   (2,380,859)   (2,999,998)	Revenue	2,055,032	2,756,769
464,425   1/5,936     Other income   618,187   610,213     Selling and distribution expenses   (34,625)   (89,096)     General and administrative expenses   (1,191,447)   (1,246,897)     Depreciation and amortization   (1,381,579)   (1,299,759)     Operating (loss) before finance cost for the year   (1,525,039)   (1,849,603)     Finance cost   (855,820)   (1,150,395)     Income (Loss) for the period   (2,380,859)   (2,999,998)     Other comprehensive income   -0-   -0-     Total comprehensive (loss) for the period   (2,380,859)   (2,999,998)     Income (Loss) per share   Image: the period   (2,380,859)   (2,999,998)     Image: the period   Image: the period   Image: the period   Image: the period     Image: the period   Image: the period   Image: the period   Image: the period   Image: the period     Image: the period   Image: the period   Image: the period   Image: the period   Image: the period     Image: the period   Image: the period   Image: the period   Image: the period   Image: the period     Image: the period   Image: the period   Im	Operating cost (Except Depreciation)	(1,590,606)	(2,580,834)
Selling and distribution expenses   (34,625)   (89,096)     General and administrative expenses   (1,191,447)   (1,246,897)     Depreciation and amortization   (1,381,579)   (1,299,759)     Operating (loss) before finance cost for the year   (1,525,039)   (1,849,603)     Finance cost   (855,820)   (1,150,395)     Income (Loss) for the period   (2,380,859)   (2,999,998)     Other comprehensive income   -0-   -0-     Total comprehensive (loss) for the period   (2,380,859)   (2,999,998)     Income (Loss) per share   Image: Share Basic and diluted (loss) per share (QR.)   (0.021)   (0.026)	Gross profit	464,425	175,936
General and administrative expenses   (1,191,447)   (1,246,897)     Depreciation and amortization   (1,381,579)   (1,299,759)     Operating (loss) before finance cost for the year   (1,525,039)   (1,849,603)     Finance cost   (855,820)   (1,150,395)     Income (Loss) for the period   (2,380,859)   (2,999,998)     Other comprehensive income   -0-   -0-     Total comprehensive (loss) for the period   (2,380,859)   (2,999,998)     Image: Cost of the period   (2,380,859)   (2,999,998)     Image: Cost of the period   -0-   -0-     Image: Cost of the period   (2,380,859)   (2,999,998)     Image: Cost of the period   -0-   -0-     Image: Cost of the period   (2,380,859)   (2,999,998)     Image: Cost of the period   -0-   -0-     Image: Cost of the period   (2,380,859)   (2,999,998)     Image: Cost of the period   -0-   -0-     Image: Cost of the period   (2,380,859)   (2,999,998)     Image: Cost of the period   -0-   -0-     Image: Cost of the period   (0,021)   (0,026)	Other income	618,187	610,213
Depreciation and amortization   (1,381,579)   (1,299,759)     Operating (loss) before finance cost for the year   (1,525,039)   (1,849,603)     Finance cost   (855,820)   (1,150,395)     Income (Loss) for the period   (2,380,859)   (2,999,998)     Other comprehensive income   -0-   -0-     Total comprehensive (loss) for the period   (2,380,859)   (2,999,998)     =====   ====   =====     (Loss) per share   (0.021)   (0.026)	Selling and distribution expenses	(34,625)	(89,096)
Operating (loss) before finance cost for the year (1,525,039) (1,849,603) Finance cost (855,820) (1,150,395) Income (Loss) for the period (2,380,859) (2,999,998) Other comprehensive income -00- Total comprehensive (loss) for the period (2,380,859) (2,999,998) ====== = = = = = = = = = = = = = = = =	General and administrative expenses	(1,191,447)	(1,246,897)
Finance cost   (855,820)   (1,150,395)     Income (Loss) for the period   (2,380,859)   (2,999,998)     Other comprehensive income   -0-   -0-     Total comprehensive (loss) for the period   (2,380,859)   (2,999,998)     =====   =====   =====     (Loss) per share   (0.021)   (0.026)	Depreciation and amortization	(1,381,579)	(1,299,759)
Income (Loss) for the period   (2,380,859)   (2,999,998)     Other comprehensive income   -0-   -0-     Total comprehensive (loss) for the period   (2,380,859)   (2,999,998)     ======   =====   ======     (Loss) per share   (0.021)   (0.026)	Operating (loss) before finance cost for the year	(1,525,039)	(1,849,603)
Other comprehensive income-0-Total comprehensive (loss) for the period(2,380,859)==========(Loss) per share(0.021)Basic and diluted (loss) per share (QR.)(0.021)	Finance cost	(855,820)	(1,150,395)
Total comprehensive (loss) for the period   (2,380,859)   (2,999,998)     = = = = =   = = = = =   = = = = =     (Loss) per share   (0.021)   (0.026)	Income (Loss) for the period	(2,380,859)	(2,999,998)
(Loss) per share Basic and diluted (loss) per share (QR.) (0.021) (0.026)	Other comprehensive income	-0-	-0-
(Loss) per share Basic and diluted (loss) per share (QR.) (0.021) (0.026)	Total comprehensive (loss) for the period		
Basic and diluted (loss) per share (QR.)(0.021)(0.026)		=====	=====
		(0.024)	
	Basic and diluted (loss) per share (QK.)		

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE THREE MONTHS ENDED MARCH 31, 2020



TM

MEDICAL DEVICES

31. March , 2020 (QAR) (Unaudited)

31. March, 2019 (QAR) (Unaudited)

Analysis of INTERIM CONDENSED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2020



### During THREE MONTHS ENDED MARCH 31,2020 the following achieved

- I. General & Admin Expenses reduced by 4%
- II. Gross profit Increase to read QAR 464,426 (22.60%)
- III. Imperilment loss nil
- IV. No Provision taken for Trade Receivables
- V. No Provision taken for slow moving items for inventory
- VI. Finance Cost reduced by 25.60%



# Thank you

Qatari German Medical Devices First Quarter, 2020 www.qgmd.com